Atossa Therapeutics Welcomes Claudia Lopez as New VP for Clinical Development
Atossa Therapeutics, Inc. (NASDAQ: ATOS) is excited to announce the recent appointment of Claudia Lopez, DVM, MSc, as its Vice President of Clinical Product Development. As a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for breast cancer, Atossa is poised for a significant advancement in its clinical endeavors.
Claudia Lopez: A Proven Leader in Clinical Development
Dr. Lopez joins Atossa with over two decades of rich experience in clinical development, emphasizing formidable leadership roles in global programs spanning immunology, oncology, and metabolic disorders. Her impressive history includes her recent position as Vice President of Clinical Development at Landos Biopharma, where she led international clinical strategies and ensured regulatory compliance for successful clinical trials.
Driving Clinical Strategies to Success
Throughout her career, Dr. Lopez has excelled in navigating complex clinical landscapes. She has a proven track record of guiding innovative treatments from initial development stages to successful regulatory outcomes. Her strategic insight will enhance Atossa’s clinical pipeline, particularly in advancing next-generation therapies for breast cancer.
Atossa's Commitment to Transformative Cancer Treatments
Dr. Steven Quay, Chief Executive Officer of Atossa Therapeutics, expressed enthusiasm about the appointment, saying, “We are thrilled to welcome Dr. Lopez to the Atossa team. Her in-depth knowledge of clinical development and her strategic vision are pivotal to our mission of delivering transformative treatments for breast cancer.” Her leadership is expected to significantly influence the direction of Atossa’s clinical programs as they strive to enhance patient outcomes across various stages of treatment.
Dr. Lopez’s Diverse Experience Across Major Pharma Companies
Dr. Lopez has amassed a wealth of experience through her roles in leading organizations like Arena Pharmaceuticals and Takeda Pharmaceuticals, where she made substantial contributions to clinical program management. Her experience includes orchestrating multidisciplinary teams, directing regulatory submissions both in the United States and Europe, and overseeing extensive clinical development initiatives in numerous therapeutic areas.
Vision for the Future: Realizing Atossa's Potential
“I am honored to be joining Atossa at a time when the company is poised for significant growth,” stated Dr. Lopez. She is enthusiastic about leveraging her experience to push forward the innovative therapies within Atossa’s pipeline. The potential for clinical advancements in breast cancer is exciting, and Dr. Lopez is dedicated to making strides in the development of these essential treatments.
About Atossa Therapeutics
Atossa Therapeutics, Inc. specializes in developing cutting-edge medicines aimed at addressing significant unmet medical needs in oncology. With a particular focus on (Z)-endoxifen, Atossa is dedicated to exploring both prevention and treatment avenues for breast cancer. Their commitment to patient care and innovative solutions is at the core of their mission.
Contact Information
For more inquiries, the company's public relations can be reached through Michael Parks, VP Investor and Public Relations at 484-356-7105 or michael.parks@atossainc.com.
Frequently Asked Questions
What role has Claudia Lopez been appointed to at Atossa Therapeutics?
Claudia Lopez has been named Vice President of Clinical Product Development at Atossa Therapeutics.
What is Atossa Therapeutics focused on?
Atossa Therapeutics is focused on developing innovative therapies for breast cancer, particularly using (Z)-endoxifen.
What are Dr. Lopez's previous roles?
Dr. Lopez previously served as Vice President of Clinical Development at Landos Biopharma and held positions at Arena Pharmaceuticals and Takeda Pharmaceuticals.
Why is Dr. Lopez's appointment significant for Atossa?
Her extensive clinical development experience and strategic expertise are expected to significantly advance Atossa’s pipeline and treatment offerings for breast cancer patients.
How can I learn more about Atossa Therapeutics?
For more information about Atossa Therapeutics and their clinical developments, you can visit their official website.
